quantum-first: flt3-itd-specific mrd clearance is associated with improved os in newly diagnosed aml
Published 1 year ago • 96 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
1:12
rationale-306: exploring pd-l1 biomarker metrics in advanced escc
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
1:59
tangible benefit for flt3-itd r/r aml on quizartinib
-
1:28
assaying flt3 variant allele frequency in aml to determine response to treatment
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
9:36
hardy-weinberg equilibrium
-
11:48
fab classification of aml pathology made easy | acute myeloid leukemia classification|#speedymedical
-
1:26
preclinical safety and efficacy of cd123-nk cell engager in r/r aml
-
3:46
variant allele frequency in patients with sf3b1-mutated mds
-
1:24
mechanisms of resistance to flt3 inhibitors in aml and strategies to overcome this
-
1:20
regulation of tetraspanin cd63 in cml progression: single-cell analysis of asymmetric hsc division
-
1:30
triplet combinations in flt3-mutated aml
-
1:42
dose escalation of ro7283420, a hla-a2-wt1 cd3 t-cell bispecific antibody, in r/r aml
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
19:32
ec'19: simple and approximately optimal pricing for proportional complementarities
-
0:39
hcc1937 transfection reagent
-
20:26
identification of actionable targets in peri-hilar cca using whole exome sequencing
-
3:35
evaluating single-agent use of flt3 inhibition in aml